Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis

Hepatology

Volumn 53, Issue 1, 2011, Pages 106-115

  Syn, Wing Kin ^a,b   Choi, Steve S ^a,c   Liaskou, Evaggelia ^b   Karaca, Gamze F ^a   Agboola, Kolade M ^a   Oo, Ye Htun ^b   Mi, Zhiyong ^a   Pereira, Thiago A ^a,d   Zdanowicz, Marzena ^a   Malladi, Padmini ^e   Chen, Yuping ^a   Moylan, Cynthia ^a,c   Jung, Youngmi ^a,f   Bhattacharya, Syamal D ^a   Teaberry, Vanessa ^a   Omenetti, Alessia ^a   Abdelmalek, Manal F ^a   Guy, Cynthia D ^a   Adams, David H ^b   Kuo, Paul C ^a   Michelotti, Gregory A ^a   Whitington, Peter F ^e   Diehl, Anna Mae ^a   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c DURHAM VA MEDICAL CENTER   (United States)

^d FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^e NORTHWESTERN UNIVERSITY   (United States)

^f Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CHOLINE; CYCLOPAMINE; METHIONINE; OSTEOPONTIN; RNA; SONIC HEDGEHOG PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE COURSE; GENETIC CODE; GENETIC TRANSCRIPTION; HYPOTHESIS; LIVER FIBROSIS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STELLATE CELL; UPREGULATION; WILD TYPE;

ANIMALS; CELL LINE; CHOLINE DEFICIENCY; DIET; FATTY LIVER; HEDGEHOG PROTEINS; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; METHIONINE; MICE; MICE, INBRED C57BL; OSTEOPONTIN; UP-REGULATION; VERATRUM ALKALOIDS;

EID: 78751479915     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23998     Document Type: Article

References (39)

1. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-443.
2. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. HEPATOLOGY 2006; 44: 27-33.
3. Feldstein AE, Papouchado BG, Angulo P, Sanderson S, Adams L, Gores GJ. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2005; 3: 384-389.
4. Jung Y, Witek RP, Syn WK, Choi SS, Omenetti A, Premont R, et al. Signals from dying hepatocytes trigger growth of liver progenitors. Gut 2010; 59: 655-665.
5. Choi SS, Omenetti A, Witek RP, Moylan CA, Syn WK, Jung Y, et al. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009; 297: G1093-G1106.
6. Syn WK, Oo YH, Pereira TA, Karaca GF, Jung Y, Omenetti A, et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. HEPATOLOGY 51: 1998-2007.
7. Syn WK, Jung Y, Omenetti A, Abdelmalek M, Guy CD, Yang L, et al. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009; 137: 1478-1488.
8. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-864.
9. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294: 1731-1735.
10. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006; 16: 79-87.
11. Miyazaki K, Okada Y, Yamanaka O, Kitano A, Ikeda K, Kon S, et al. Corneal wound healing in an osteopontin-deficient mouse. Invest Ophthalmol Vis Sci 2008; 49: 1367-1375.
12. Fujita N, Fujita S, Okada Y, Fujita K, Kitano A, Yamanaka O, et al. Impaired angiogenic response in the corneas of mice lacking osteopontin. Invest Ophthalmol Vis Sci 2010; 51: 790-794.
13. Lorena D, Darby IA, Gadeau AP, Leen LL, Rittling S, Porto LC, et al. Osteopontin expression in normal and fibrotic liver. Altered liver healing in osteopontin-deficient mice. J Hepatol 2006; 44: 383-390.
14. Das S, Harris LG, Metge BJ, Liu S, Riker AI, Samant RS, et al. The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J Biol Chem 2009; 284: 22888-22897.
15. Diao H, Kon S, Iwabuchi K, Kimura C, Morimoto J, Ito D, et al. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 2004; 21: 539-550.
16. Lee SH, Seo GS, Park YN, Yoo TM, Sohn DH. Effects and regulation of osteopontin in rat hepatic stellate cells. Biochem Pharmacol 2004; 68: 2367-2378.
17. Whitington PF, Malladi P, Melin-Aldana H, Azzam R, Mack CL, Sahai A. Expression of osteopontin correlates with portal biliary proliferation and fibrosis in biliary atresia. Pediatr Res 2005; 57: 837-844.
18. Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 2004; 287: G264-G273.
19. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
20. Yata Y, Gotwals P, Koteliansky V, Rockey DC. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. HEPATOLOGY 2002; 35: 1022-1030.
21. Choi SS, Witek RP, Yang L, Omenetti A, Syn WK, Moylan CA, et al. Activation of Rac1 promotes hedgehog-mediated acquisition of the myofibroblastic phenotype in rat and human hepatic stellate cells. HEPATOLOGY 2010; 52: 278-290.
22. Heilmann K, Hoffmann U, Witte E, Loddenkemper C, Sina C, Schreiber S, et al. Osteopontin as two-sided mediator of intestinal inflammation. J Cell Mol Med 2009; 13: 1162-1174.
23. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009; 17: 153-161.
24. Yahagi K, Ishii M, Kobayashi K, Ueno Y, Mano Y, Niitsuma H, et al. Primary culture of cholangiocytes from normal mouse liver. In Vitro Cell Dev Biol Anim 1998; 34: 512-514.
25. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology 2005; 128: 1354-1368.
26. Omenetti A, Diehl AM. The adventures of sonic hedgehog in development and repair. II. Sonic hedgehog and liver development, inflammation, and cancer. Am J Physiol Gastrointest Liver Physiol 2008; 294: G595-G598.
27. Mori R, Shaw TJ, Martin P. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med 2008; 205: 43-51.
28. Morimoto J, Inobe M, Kimura C, Kon S, Diao H, Aoki M, et al. Osteopontin affects the persistence of beta-glucan-induced hepatic granuloma formation and tissue injury through two distinct mechanisms. Int Immunol 2004; 16: 477-488.
29. Berman JS, Serlin D, Li X, Whitley G, Hayes J, Rishikof DC, et al. Altered bleomycin-induced lung fibrosis in osteopontin-deficient mice. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1311-L1318.
30. Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008; 23: 1635-1648.
31. Syn WK, Teaberry V, Choi SS, Diehl AM. Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitis. Semin Liver Dis 2009; 29: 200-210.
32. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002; 123: 1323-1330.
33. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. HEPATOLOGY 2003; 38: 1188-1198.
34. Witek RP, Yang L, Liu R, Jung Y, Omenetti A, Syn WK, et al. Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. Gastroenterology 2009; 136: 320-330.
35. Syn WK, Witek RP, Curbishley SM, Jung Y, Choi SS, Enrich B, et al. Role for hedgehog pathway in regulating growth and function of invariant NKT cells. Eur J Immunol 2009; 39: 1879-1892.
36. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Choi SS, et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008; 118: 3331-3342.
37. Tajiri K, Shimizu Y, Tsuneyama K, Sugiyama T. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009; 21: 673-680.
38. Huang W, Zhu G, Huang M, Lou G, Liu Y, Wang S. Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. Clin Chim Acta 2010; 411: 675-678.
39. Fickert P, Thueringer A, Moustafa T, Silbert D, Gumhold J, Tsybrovskyy O, et al. The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice. Lab Invest 2010; 90: 844-852.